ArticleFrontiers in microbiology2021
Novel Cyclic Lipopeptides Fusaricidin Analogs for Treating Wound Infections.
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Fusaricidins producing Paenibacillus: a potential biocontrol agent against plant pathogens.Archives of microbiology · 2026Review
- Cathelicidin-like Peptide for ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Unveiling a New Antimicrobial Peptide with Efficacy againstAntibiotics (Basel, Switzerland) · 2024Article
- Staphylococcus aureus and biofilms: transmission, threats, and promising strategies in animal husbandry.Journal of animal science and biotechnology · 2024Review
- Breakthrough treatments for accelerated wound healing.Science advances · 2023Review
- Biocontrol potential of lipopeptides produced byFrontiers in microbiology · 2023Article
- Effect ofMolecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Both acute and chronic cutaneous wounds are often difficult to treat due to the high-risk for bacterial contamination. Once hospitalized, open wounds are at a high-risk for developing hospital-associated infections caused by multi drug-resistant bacteria such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.